Published in Health Business Week, April 2nd, 2010
Boehringer Ingelheim to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. 4-Antibody will use its proprietary and unencumbered Hu-PAC® and Retrocyte Display® technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim. 4-Antibody AG will receive payments of up to EUR 177.5 million (CHF 266 million) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones. Further financial details were not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.